MEET HOPE HEAD ON.

2023 Impact Report
Wow! Thanks to your support, our 50th anniversary year in 2023 was groundbreaking. Not only did we meet our fundraising goal—we also served more patients and their families than ever before!

But as our founder Susan Kramer has said, “more must be done.” And with your help, we’re doing just that. Read on and you’ll see that **77.6% of every dollar raised goes directly to our mission.** You’ll also see our progress in three key areas: research, patient & caregiver support and advocacy.

Together, we’re Meeting Hope Head On.

Thanks for your unwavering support,

Ralph DeVitto, President & CEO

---

MEETING HOPE HEAD ON

We’re grateful for advocates like you, including: GBM Survivor Neill Ferrill and Caregiver Robin Ferrill; ABTA Founder Susan Kramer; and Ugonma Chukwueke, MD, MPH, Neuro-Oncologist, Dana-Farber Cancer Institute, among many others.
2023 FINANCIALS

Thanks to you, we’re closer to our goal!

In 2023 the ABTA recognized its 50th anniversary by launching Meet Hope Head On—a five-year, $50-million fundraising campaign to give us the resources we need to triple our research investment, double the patients we serve, and double federal funding for brain tumor research.

Your support helped the ABTA raise $8.8 million of our $50-million goal AND made an impact.

In fiscal year 2023, 77.6% of the funds raised by the American Brain Tumor Association were allocated to research and patient service programs.

Revenue

- Contributions $5,474,384 (64.2%)
- Corporate & Foundations $2,336,440 (27.4%)
- Fundraising Events $1,981,866 (23.3%)
- Individuals $1,724,869 (20.2%)
- Estates/Bequests $1,413,075 (16.6%)
- Other Income $1,065,743 (12.5%)

Expenses

- Program Services $5,752,062 (77.6%)
- Medical & Scientific Research $2,773,691 (37.4%)
- Patient & Caregiver Support $2,043,279 (27.6%)
- Outreach $935,092 (12.6%)
- Management & General $974,002 (13.1%)
- Fundraising $689,681 (9.3%)

(77.6% of every dollar raised goes to our Mission)

*Unaudited numbers as of March 2024.*
In 2023 we awarded over $1.47 million to 24 researchers—our largest funding investment in 10 years! Research projects included: investigating biomarkers, DNA damage and repair mechanisms, gene therapies, and more, across adult and pediatric primary and metastatic brain tumors.

We also hosted our 12th Alumni Research Network meeting (pictured above), convening ABTA-funded researchers from around the world to accelerate scientific exchange, encourage collaboration and provide resources for career development.

$35 million investment  More than 700 researchers  More than 800 research projects

More than 80% of grade-2 glioma tumors contain IDH mutations that boost tumor growth. IDH mutations were discovered through your donations by ABTA-supported research in 2009. With the discovery of IDH mutations, an investigational targeted therapy—vorasidenib—has been developed specifically for low-grade gliomas with studies showing delayed cancer growth beyond two years and reduced risk of cancer progression or death by 61%. Today, vorasidenib is under review by the FDA.
PATIENT & CAREGIVER SUPPORT

From free, best-in-class information to social and emotional support, the ABTA continues to provide vital resources and services to patients and their families. And thanks to virtual access to our programs, the ABTA is reaching more people than ever before. In 2023, we had over 400,000 website visitors and more than 180,000 views of our YouTube educational library.

Because of you, we reached more patients than ever before.

More than 100,000 served this year!

- 181,900 views of our YouTube educational library in 2023
- 58,000 social media followers
- 36,000 educational brochure downloads in 2023
- 37,457 Connections online community members
- 3,248 registrants for in-person and virtual programs in 2023
We’re mobilizing brain tumor community advocates to influence federal policies and increase awareness.

Ram Subramanian, Chair of the Board; Ralph DeVitto, President & CEO; and Nicole Willmarth, PhD, Chief Mission Officer, attend the Eleventh Annual Rally for Medical Research in September.

In May, leaders including ABTA’s Chief Mission Officer Nicole Willmarth, PhD, gathered in Washington D.C. for The White House Cancer Moonshot Initiative’s Brain Cancers Forum.

The ABTA Volunteer Leadership Advisory Council gathers at the 2023 ABTA National Conference.

Long-time volunteer Sally Walker receives the Juliana Schafer Spirit of Hope Award at the 2023 ABTA National Conference.

The International Brain Tumour Alliance and the ABTA convene the first-ever patient advocacy symposium focused on brain metastases.
From individual donors, foundations, and corporate sponsors—to our Team ABTA members and Breakthrough for Brain Tumors (BT5K) participants—your generosity gives patients and their families hope. Together, we’re investing in groundbreaking research and patient services that have the power to change lives!

Together, we’re making life-changing research and support possible.

BT5K
Nine walks raised $1,179,013

FUNDRAISE YOUR WAY
54 events raised $523,311

TEAM ABTA
153 team members raised $500,057

COMMUNITY MILESTONES

- 1,100+ Facebook fundraisers
- 161 sustaining donors
- 55 corporate sponsors
ABOUT THE ABTA

Founded in 1973, the American Brain Tumor Association (ABTA) was the first national nonprofit advocacy organization dedicated solely to brain tumors.

For more than 50 years the ABTA has served as the champion of the brain tumor community, across all ages and tumor types, by providing comprehensive resources to support the complex needs of brain tumor patients and caregivers and funding innovative research in the pursuit of breakthroughs in brain tumor diagnoses, treatments, and care.

Vision

A future where not one life is lost to a brain tumor.

Mission Statement

To advance the understanding and treatment of brain tumors with the goals of improving, extending and, ultimately, saving the lives of those impacted by a brain tumor diagnosis. We do this through interactions and engagements with brain tumor patients and their families, collaborations with allied groups and organizations, and the funding of brain tumor research.

The ABTA is proud to receive high rankings for financial accountability and transparency.